The abstract submission is now closed!
Accepted abstracts are available online
Abstract submission deadline
Deadline |
Date and Time |
|---|---|
Abstracts |
6 January 2021, 21:00 CET (Central European Time) |
Outcome notifications
Outcome notifications are expected to be made available to first authors by mid-January 2021.
Abstract submission categories
- Immunotherapy
- Kinase-targeting agents
- Antibody-based therapies
- Epigenetics
- DNA damage repair
- Cell therapy
- Miscellaneous
Presentation and publication of abstracts accepted for TAT 2021
The TAT 2021 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:
- Proffered Paper (oral presentation) – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short presentation by authors with comment and interactive audience discussion led by an invited expert.
- Poster – An important method for communicating details of scientific research, posters will be on display for the duration of the Congress.
All accepted abstracts will be published as a supplement to the official ESMO journal, Annals of Oncology.
Publication schedule for accepted abstracts:
Abstracts accepted for presentation at TAT 2021 as Proffered Paper (oral presentation), Mini Oral and Poster will be published online on the ESMO website at 08:00 CET on Monday, 1 March 2021.
Abstracts |
Date and Time |
|---|---|
|
Abstracts accepted as:
|
Monday, 1 March 2021 |
Registration Grants
A restricted number of registration grants to TAT 2021 are available, upon application, to first author (= presenter) of candidates under the age of 40 who submit abstracts considered deserving of recognition. Selection will be made by the TAT 2021 Scientific Committee on a competitive basis from among the accepted abstracts.